(Reuters) -Regeneron shares fell 9% before the bell on Friday after its experimental drug for patients with a type of lung ...

Anal cancer is relatively uncommon, accounting for approximately 2.5% of all gastrointestinal cancers. Nonetheless, its ...

This was the stock's third consecutive day of gains.

Bristol-Myers Squibb Chief Executive Chris Boerner said at The Wall Street Journal's Future of Everything festival on Thursday that potential tariffs targeting the drug industry from the Trump ...

That conversation changed everything. Stylianos took her advice, enrolled at Rutgers as a biology major and set his sights on ...

Bristol Myers Squibb recently snagged an upgrade from hold to buy, thanks to an attractive stock correction and rising ...

Combined with the last dividend raise by +3.3% in December 2024, building upon the 10Y growth profile at +5.27%, we believe ...

EpiVax, Inc., a leader in preclinical immunogenicity assessment for biologic therapeutics and vaccines, is pleased to announce the appointment ...

Bristol Myers Squibb is juggling financial wins and market challenges while pushing its promising drug pipeline forward. The ...

Bristol-Myers Squibb Company's undervaluation offers over 20% upside potential despite headwinds. Click here to find out why ...